✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Clinical Summary This regulatory notice documents the Drug...
Cannabinoid formulation patent describes improved controlled-release profile #6
A patent filing describes a controlled-release cannabinoid composition with potential therapeutic applications.
Therapeutic potential and pharmacological mechanisms of cannabinoids in alleviating chemotherapy-induced organ toxicity and adverse effects.
A comprehensive review examines how cannabinoids chemotherapy organ protection mechanisms could address treatment-limiting toxicities. While theoretical evidence suggests promise through anti-inflammatory and antioxidant pathways, clinical validation remains necessary before therapeutic recommendations.
Cannabis Rescheduling Is Not the Story People Think It Is
The cannabis rescheduling clinical impact is being widely misunderstood. While federal policy shifts from Schedule I to Schedule III signal progress, they do not define how cannabis should be used in medical care. This analysis clarifies what changes, what does not, and what clinicians and patients should actually take from this moment.
Cannabis Brain Health and Aging Brain: Beyond the Headlines
Public discussions regarding cannabis brain health and aging often fail to distinguish between recreational adolescent use and late-life therapeutic guidance. This clinical review breaks down recent data to show why the exposure definition and habit structure are critical to understanding cognitive outcomes. Discover how structured medical oversight can shift the impact of cannabis from cognitive friction to functional support.
How Cannabis Interacts With the Aging Brain and Its Endocannabinoid System
Cannabis aging brain endocannabinoid system research shows that baseline endocannabinoid tone declines with age. This study demonstrates that cannabis produces larger proportional increases in key compounds like anandamide in older adults. These findings help explain why aging patients often experience different and sometimes more pronounced responses to cannabis.
A Physicianโs Interpretation of a 2,500-Study Review
Medical cannabis evidence remains more limited than many patients expect. A large JAMA review of over 2,500 studies highlights where clinical support exists and where it does not. This analysis clarifies what current medical cannabis evidence can responsibly support in practice.
Is Cannabis Effective for ADHD?
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchMental HealthNeurologySafety Why This Matters Clinicians need to understand the current evidence base for cannabis...
Zurich’s Weed Trial Is Working So Well Switzerland Just Extended It Again | High Times
✦ New CED Clinical Relevance #80High Clinical Relevance Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News | CED Clinic PolicyAccess ModelsInternational ResearchClinical ImplementationRegulatory Framework Why This MattersReal-world policy implementations provide crucial data...
Cannabinoid-based interventions for behavioral outcomes in children and adolescents with autism spectrum disorder: A systematic review of safety and effectiveness.
Autism spectrum disorder (ASD) lacks effective options for core symptoms. Cannabinoids, especially cannabidiol (CBD) and combined CBD:ฮ9-tetrahydrocannabinol…